How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
53
OMER Quote, Financials, Valuation and Earnings
Last price:
$11.70
Seasonality move
:
12.03%
Day range:
$11.61 - $12.17
52-week range:
$2.95 - $17.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.4M
Avg. volume:
3.6M
1-year change:
32.24%
Market cap:
$828.8M
Revenue:
--
EPS (TTM):
-$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OMER
Omeros Corp.
|
-- | $0.16 | -- | -2.38% | $38.00 |
|
DARE
Daré Bioscience, Inc.
|
$765K | -$0.43 | 2911.81% | -13.48% | $10.75 |
|
EWTX
Edgewise Therapeutics, Inc.
|
-- | -$0.44 | -- | -6.86% | $38.17 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $204.63 |
|
RGNX
REGENXBIO, Inc.
|
$59.3M | -$0.78 | -23.59% | -24.34% | $31.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$139.5K | -$0.49 | -40.39% | -5.71% | $0.97 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OMER
Omeros Corp.
|
$11.69 | $38.00 | $828.8M | -- | $0.00 | 0% | -- |
|
DARE
Daré Bioscience, Inc.
|
$1.81 | $10.75 | $25.9M | 95.38x | $0.00 | 0% | 365.38x |
|
EWTX
Edgewise Therapeutics, Inc.
|
$28.15 | $38.17 | $3B | -- | $0.00 | 0% | -- |
|
GOVX
GeoVax Labs, Inc.
|
$2.80 | $204.63 | $4.8M | -- | $0.00 | 0% | 2.88x |
|
RGNX
REGENXBIO, Inc.
|
$11.16 | $31.00 | $565M | -- | $0.00 | 0% | 3.53x |
|
VTGN
Vistagen Therapeutics, Inc.
|
$0.56 | $0.97 | $22M | -- | $0.00 | 0% | 19.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OMER
Omeros Corp.
|
254.22% | -2.814 | 126.5% | 0.76x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.066 | 27.91% | 1.09x |
|
EWTX
Edgewise Therapeutics, Inc.
|
0.74% | 0.924 | 0.24% | 26.03x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.979 | -- | 2.75x |
|
RGNX
REGENXBIO, Inc.
|
62.42% | -0.953 | 54.89% | 2.40x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 1.873 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
EWTX
Edgewise Therapeutics, Inc.
|
-$570K | -$46.9M | -30.86% | -31.13% | -- | -$34.9M |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
RGNX
REGENXBIO, Inc.
|
$20.1M | -$52.4M | -40.97% | -73.5% | -176.27% | -$56.5M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
Omeros Corp. vs. Competitors
-
Which has Higher Returns OMER or DARE?
Daré Bioscience, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -154904.35%. Omeros Corp.'s return on equity of -- beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OMEROmeros Corp.-- -$0.47 $143M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About OMER or DARE?
Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 225.06%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 493.92%. Given that Daré Bioscience, Inc. has higher upside potential than Omeros Corp., analysts believe Daré Bioscience, Inc. is more attractive than Omeros Corp..
Company Buy Ratings Hold Ratings Sell Ratings OMEROmeros Corp.2 2 0 DAREDaré Bioscience, Inc.3 0 0 -
Is OMER or DARE More Risky?
Omeros Corp. has a beta of 2.380, which suggesting that the stock is 138.029% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.
-
Which is a Better Dividend Stock OMER or DARE?
Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMER or DARE?
Omeros Corp. quarterly revenues are --, which are smaller than Daré Bioscience, Inc. quarterly revenues of $2.3K. Omeros Corp.'s net income of -$21.2M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 365.38x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMEROmeros Corp.-- -- -- -$21.2M DAREDaré Bioscience, Inc.365.38x 95.38x $2.3K -$3.6M
-
Which has Higher Returns OMER or EWTX?
Edgewise Therapeutics, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of --. Omeros Corp.'s return on equity of -- beat Edgewise Therapeutics, Inc.'s return on equity of -31.13%.
Company Gross Margin Earnings Per Share Invested Capital OMEROmeros Corp.-- -$0.47 $143M EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M -
What do Analysts Say About OMER or EWTX?
Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 225.06%. On the other hand Edgewise Therapeutics, Inc. has an analysts' consensus of $38.17 which suggests that it could grow by 35.58%. Given that Omeros Corp. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Edgewise Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMEROmeros Corp.2 2 0 EWTXEdgewise Therapeutics, Inc.7 2 0 -
Is OMER or EWTX More Risky?
Omeros Corp. has a beta of 2.380, which suggesting that the stock is 138.029% more volatile than S&P 500. In comparison Edgewise Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OMER or EWTX?
Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. Edgewise Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMER or EWTX?
Omeros Corp. quarterly revenues are --, which are smaller than Edgewise Therapeutics, Inc. quarterly revenues of --. Omeros Corp.'s net income of -$21.2M is higher than Edgewise Therapeutics, Inc.'s net income of -$40.7M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Edgewise Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus -- for Edgewise Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMEROmeros Corp.-- -- -- -$21.2M EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M
-
Which has Higher Returns OMER or GOVX?
GeoVax Labs, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -630.04%. Omeros Corp.'s return on equity of -- beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital OMEROmeros Corp.-- -$0.47 $143M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About OMER or GOVX?
Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 225.06%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $204.63 which suggests that it could grow by 7208.04%. Given that GeoVax Labs, Inc. has higher upside potential than Omeros Corp., analysts believe GeoVax Labs, Inc. is more attractive than Omeros Corp..
Company Buy Ratings Hold Ratings Sell Ratings OMEROmeros Corp.2 2 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is OMER or GOVX More Risky?
Omeros Corp. has a beta of 2.380, which suggesting that the stock is 138.029% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.675, suggesting its more volatile than the S&P 500 by 267.454%.
-
Which is a Better Dividend Stock OMER or GOVX?
Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMER or GOVX?
Omeros Corp. quarterly revenues are --, which are smaller than GeoVax Labs, Inc. quarterly revenues of --. Omeros Corp.'s net income of -$21.2M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 2.88x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMEROmeros Corp.-- -- -- -$21.2M GOVXGeoVax Labs, Inc.2.88x -- -- -$6.3M
-
Which has Higher Returns OMER or RGNX?
REGENXBIO, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -208.32%. Omeros Corp.'s return on equity of -- beat REGENXBIO, Inc.'s return on equity of -73.5%.
Company Gross Margin Earnings Per Share Invested Capital OMEROmeros Corp.-- -$0.47 $143M RGNXREGENXBIO, Inc.67.68% -$1.20 $429.6M -
What do Analysts Say About OMER or RGNX?
Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 225.06%. On the other hand REGENXBIO, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 177.78%. Given that Omeros Corp. has higher upside potential than REGENXBIO, Inc., analysts believe Omeros Corp. is more attractive than REGENXBIO, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMEROmeros Corp.2 2 0 RGNXREGENXBIO, Inc.6 1 0 -
Is OMER or RGNX More Risky?
Omeros Corp. has a beta of 2.380, which suggesting that the stock is 138.029% more volatile than S&P 500. In comparison REGENXBIO, Inc. has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.832%.
-
Which is a Better Dividend Stock OMER or RGNX?
Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. REGENXBIO, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. REGENXBIO, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMER or RGNX?
Omeros Corp. quarterly revenues are --, which are smaller than REGENXBIO, Inc. quarterly revenues of $29.7M. Omeros Corp.'s net income of -$21.2M is higher than REGENXBIO, Inc.'s net income of -$61.9M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while REGENXBIO, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 3.53x for REGENXBIO, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMEROmeros Corp.-- -- -- -$21.2M RGNXREGENXBIO, Inc.3.53x -- $29.7M -$61.9M
-
Which has Higher Returns OMER or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -7525.97%. Omeros Corp.'s return on equity of -- beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital OMEROmeros Corp.-- -$0.47 $143M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About OMER or VTGN?
Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 225.06%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 73.18%. Given that Omeros Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMEROmeros Corp.2 2 0 VTGNVistagen Therapeutics, Inc.0 5 0 -
Is OMER or VTGN More Risky?
Omeros Corp. has a beta of 2.380, which suggesting that the stock is 138.029% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.307, suggesting its less volatile than the S&P 500 by 69.277%.
-
Which is a Better Dividend Stock OMER or VTGN?
Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMER or VTGN?
Omeros Corp. quarterly revenues are --, which are smaller than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Omeros Corp.'s net income of -$21.2M is lower than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 19.59x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMEROmeros Corp.-- -- -- -$21.2M VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
